Posted by Michael Wonder on 15 Oct 2021
FDA approves atezolizumab as adjuvant treatment for non-small-cell lung cancer
15 October 2021 - Today, the FDA approved atezolizumab (Tecentriq) for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small-cell lung cancer whose tumours have PD-L1 expression on ≥ 1% of tumour cells, as determined by an FDA approved test.
Today, the FDA also approved the Ventana PD-L1 (SP263) Assay (Ventana) as a companion diagnostic device to select patients with non-small-cell lung cancer for adjuvant treatment with Tecentriq.
